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Association of non-alcoholic fatty liver disease with 
cardiovascular disease and subclinical atherosclerosis
Rahul Sao, Wilbert S. Aronow
A b s t r a c t
Non-alcoholic fatty liver disease (NAFLD) refers to fatty infiltration of liver 
in the absence of significant alcohol intake, use of steatogenic medication, 
or hereditary disorders. It is a common cause of chronic liver disease with 
a worldwide estimated prevalence ranging from 6.3% to 33%. The NAFLD is 
considered a hepatic manifestation of the metabolic syndrome. Insulin resis-
tance and increased oxidative stress are central to pathogenesis of NAFLD, 
and risk factors include metabolic syndrome, diabetes mellitus, obesity, lack 
of physical activity, smoking, and high fat diet. NAFLD is associated with 
higher mortality as compared to the general population with cardiovascular 
disease being the most common cause of death. The NAFLD is associated 
with a higher prevalence of subclinical atherosclerosis as evidenced by odds 
of higher coronary artery calcification, higher average and maximum carotid 
intima-media thickness. It is also associated with stiff arteries as evidenced 
by higher cardio-ankle vascular index and higher brachial-ankle pulse wave 
velocity. Increasing evidence has linked NAFLD with atherosclerotic car-
diovascular diseases. The NAFLD is associated with a higher prevalence of 
coronary artery disease (CAD), more severe CAD, poor coronary collateral 
development, and higher incidence of coronary events. The NAFLD is also 
associated with ischemic stroke. Studies have shown that the association 
between NAFLD and atherosclerotic cardiovascular diseases is independent 
of shared risk factors.
Key words: non-alcoholic fatty liver disease, coronary artery disease, 
atherosclerotic cardiovascular disease.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic 
liver disease with increasing worldwide prevalence. Non-alcoholic fatty 
liver disease is defined by imaging or histological evidence of fatty in-
filtration of liver in the absence of known causes of fat accumulation in 
the liver including significant alcohol consumption [1]. Non-alcoholic fatty 
liver disease is a spectrum of disease ranging from simple steatosis (NAFL 
or non-alcoholic fatty liver) without evidence of hepatocellular injury to 
non-alcoholic steatohepatitis (NASH) marked by inflammation with he-
patocyte injury with or without fibrosis [1, 2]. Non-alcoholic fatty liver dis-
ease may or may not be associated with aminotransferase elevation [1]. 
Due to widespread availability and low cost, ultrasound is the pre-
ferred initial radiological study to assess for fatty infiltration of liver [3, 4]. 
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Non-alcoholic steatohepatitis represents more ad-
vanced stage of the disease and has an inflam-
matory component in addition to fat accumula-
tion [1]. Non-alcoholic steatohepatitis may further 
progress to cirrhosis and or to hepatocellular car-
cinoma [5]. Various non-invasive methods such as 
the NAFLD fibrosis score [6], Enhanced Liver Fibro-
sis (ELF) panel, presence of circulating biomarkers 
(cytokeratin-18) can identify advanced fibrosis 
[7]. However, liver biopsy is the ‘gold standard’ for 
assessing the histology in NAFLD and accurately 
identifying NASH. Metabolic syndrome predicts 
the presence of steatohepatitis in NAFLD patients 
and its presence should guide the decision to ob-
tain liver biopsy [1]. 
Non-alcoholic fatty liver disease is sometimes 
referred to as the hepatic manifestation of meta-
bolic syndrome [8, 9]. It is associated with higher 
overall mortality as compared to the general pop-
ulation [10, 11]. Cardiovascular diseases are the 
most common cause of death among patients 
with NAFLD [9–11] while liver disease is the third 
leading cause [11, 12]. The aim of this paper is to 
review the available literature linking NAFLD and 
cardiovascular disease. 
Because of shared risk factors with the meta-
bolic syndrome, NAFLD was considered as a mere 
marker of cardiovascular disease. However, stud-
ies are available that show an association between 
cardiovascular disease and NAFLD independent of 
shared risk factors [13–16].
Epidemiology
The reported incidence of NAFLD varies wide-
ly. A  retrospective analysis reported an annual 
incidence of 29 per 100,000 patient years [17]. 
Another prospective study in a  Japanese popu-
lation reported 308 new cases among 3147 pa-
tients during a 414 days follow-up period [18]. 
The wide variation in reporting indicates the 
need for a  better study to calculate the actual 
incidence rates. 
The prevalence of NAFLD has been increasing in 
recent times. The reported prevalence varies based 
on the population studied and modality used to 
establish the diagnosis. The worldwide prevalence 
in the general population ranges from 6.3% to 
33% with a  median of 20% [1]. The prevalence 
is much higher in a high-risk patient population. 
Machado et al combined 12 observational stud-
ies including 1620 patients with morbid obesity 
and reported a 91% prevalence (range: 85–98%) 
of NAFLD in this population group [19]. Two sep-
arate studies quoted a  prevalence of ultrasono-
graphic NAFLD in diabetic patients at 69.4% [20] 
and 67.8% [21]. Another study in patients referred 
to a  urban hospital-based lipid clinic showed 
a NAFLD prevalence of 50% [22]. 
Etiopathogenesis and risk factors 
Day and James explained the pathogenesis 
of NAFLD in 1998 by ‘two-hit hypothesis’ [23]. 
The first physiological event is insulin resistance. 
Insulin resistance manifests not only at the lev-
el of muscles but also at the level of liver and 
adipose tissue [24]. The combined effect of hy-
perinsulinemia and insulin resistance leads to 
an increased absolute hepatic free fatty acid up-
take and increased esterification to triglycerides 
among other mechanisms leading to hepatic 
steatosis [25]. It should be stressed that insulin 
resistance is a cause of NAFLD rather than being 
its effect as shown by studies in genetically pre-
disposed NAFLD subjects who have insulin sen-
sitivity comparable to matched subjects without 
NAFLD [26–28].
The second physiological event is increased oxi-
dative stress [25, 29]. Oxidative stress plays a dual 
role by contributing to steatosis due to higher per-
oxidation of lipids and by promoting progression 
of steatosis to steatohepatitis. A study has shown 
a higher rate of lipid oxidation and impaired sup-
pression of hepatic lipid oxidation by insulin in 
patients with NAFLD [24]. 
With better understanding of the pathogene-
sis of NAFLD, a  ‘multiple parallel hits’ hypothesis 
has gained more acceptance [30, 31]. Insulin re-
sistance and its metabolic disturbance constitute 
the first hit resulting to fat infiltration of liver. This 
is followed by multiple parallel hits, leading to he-
patocyte injury and progression from simple ste-
atosis to NASH and fibrosis [30]. 
Cytokines play an important role in insulin resis-
tance and NAFLD [32]. Higher levels of pro-inflam-
matory cytokine tumor necrosis factor-α (TNF-α) 
are associated with increased insulin resistance 
[33]. Mice lacking TNF-α were shown to have im-
proved insulin sensitivity [34]. Haukeland et al. 
demonstrated higher levels pro-inflammatory cy-
tokines interleukin-6 (IL-6), chemokine ligand 2/ 
monocyte chemoattractant protein-1 (CCL-2/
MCP-1), TNF-α and decreased level of adiponectin 
among patients with NAFLD compared to controls 
[35]. IL-6 expression is markedly increased in pa-
tients with NASH as compared to patients with 
NAFLD or normal liver histology [36]. Anti-inflam-
matory adipocytokine adiponectin levels are lower 
in patients with hepatic steatosis and NASH [37].
Obesity has a  strong correlation with insulin 
resistance and NAFLD [38–40]. The prevalence of 
NAFLD among morbidly obese patients based on 
a  meta-analysis was 91% (range: 85–98%) [19]. 
There is evidence that weight loss among obese 
patient with type II diabetes mellitus can normal-
ize insulin sensitivity [41]. Another study showed 
that weight loss can prevent progression of glu-
cose intolerance to type II diabetes mellitus [42]. 
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Choudhary et al. prospectively studied 16 liv-
ing related liver donors with significant steatosis 
based on liver histology. Donors were recommend-
ed 1200 Kcal/day diet and 60 min/day moderate 
cardiovascular training. Repeat liver biopsy done at 
28 ±10 days showed a decrease in steatosis in all 
but one subject including normalization of the liver 
biopsy in 7 donors [43]. A review of the literature of 
bariatric surgery showed significant improvement 
and resolution of steatosis with bariatric surgery 
[44]. However, in patients with established hepatic 
fibrosis, there are conflicting data about the out-
come of metabolic procedures. Some studies have 
shown that metabolic procedures are associated 
with worsening of fibrosis in patients with ad-
vanced fibrosis [45, 46]. However, a few including 
prospective studies have also shown improvement 
in fibrosis after a bariatric procedure [45, 47]. 
The use of exercise is a  well-established pre-
vention and therapeutic recommendation for 
NAFLD [48]. Increased physical activity not only 
plays a protective role against many risk factors of 
NAFLD such as obesity, metabolic syndrome, hy-
perlipidemia, and insulin resistance, but also has 
independent beneficial effects. In a cross-section-
al study, physical activity was inversely proportion-
al to the prevalence of NAFLD in a dose dependent 
manner that was independent of visceral obesity 
and insulin resistance [49]. Another cross-sec-
tional analysis of non-diabetic Korean individuals 
showed that regular exercise was associated with 
a reduced risk of having NAFLD and decreased liv-
er enzymes in patients with NAFLD [50]. 
Smoking has been implicated as a  risk factor 
for NAFLD in several case control studies. Three 
separate studies in a Chinese population has es-
tablished cigarette smoking as risk factors and 
its interaction with genetic polymorphisms of 
MCP-1 receptor CCR2 gene 190A/G (GG), NADPH 
oxidase subunit p22phox gene C242T [51], LEPR 
gene Gln223Arg, MnSOD9Ala/Val [52], AdipoR2 
gene +33371Gln/Arg, and CYP2E1-Rsa I  [53], in-
creasing the risk even further. The odds of cases 
being smokers as compared to controls in these 
three studies were 3.3032 [51], 3.6754 [52], and 
2.5919 [53].
High fat diet is a precursor for insulin resistance 
[54] and a risk factor for NAFLD. Wiedemann et al. 
showed induction of hepatic insulin resistance by 
4 days of a high fat diet (52% fat calories) in mice 
[55]. Pan et al. have shown that more than 70% of 
mice that were a fed high fat diet (42% fat calo-
ries) developed NAFLD at 12 weeks [56]. 
Non-alcoholic fatty liver disease and 
subclinical atherosclerosis
Insulin resistance is the cornerstone of NAFLD 
pathogenesis and is closely associated with the 
metabolic syndrome. Non-alcoholic fatty liver dis-
ease, insulin resistance, and the metabolic syn-
drome share multiple risk factors. Some authors 
have referred to NAFLD as a hepatic manifestation 
of the metabolic syndrome. Non-alcoholic fatty liv-
er disease accelerates development and progres-
sion of atherosclerosis. However, disagreement 
exists whether NAFLD is a  risk factor of athero-
sclerosis beyond its association with the metabolic 
syndrome [57]. Studies are available that show an 
association between NAFLD and subclinical ath-
erosclerosis. Most of them prove this association 
is independent of the metabolic syndrome and tra-
ditional cardiovascular risk factors (Table I).
Coronary artery calcification (CAC) is a  surro-
gate marker for atherosclerotic burden and an 
independent marker of coronary heart disease 
(CHD) risk [58]. Sung et al. analyzed data from 
a  South Korean occupational cohort of 10,153 
individuals who received an ultrasound of the 
abdomen for assessment of fatty liver and a car-
diac computerized tomography (CT) computed 
CAC score. Fatty liver was associated with a CAC 
score > 0, independent of all metabolic syndrome 
features (OR = 1.21; 95% CI: 1.01–1.45) [59]. An 
evaluation of 505 non diabetic, asymptomatic 
men free of known CHD showed a  positive cor-
relation between hepatic steatosis diagnosed by 
ultrasound and CAC quantified by an electron 
beam tomography scan. The prevalence of CAC 
was higher among patients with hepatic steato-
sis (52% vs. 37%, p = 0.001). This association was 
statistically significant after adjustment for age, 
CHD risk factors, and liver enzymes [60]. 
Another study included 2424 participants from 
the Coronary Artery Risk Development in Young 
Adult Study [61]. This study used CT to quantify 
liver fat, CAC, and abdominal aortic calcification 
(AAC). Patients with NAFLD had an increased prev-
alence of CAC (37.9% vs. 26.0%; p < 0.001) and 
AAC (65.1% vs. 49.9%; p < 0.001). The associa-
tion of NAFLD with CAC and AAC persisted after 
adjustment for demographics and health behav-
iors. However, this association did not reach sta-
tistical significance after adjustment for visceral 
adipose tissue [61]. A more recent study involved 
a cross-sectional analysis of 3796 participants in 
the Multi-Ethnic Study of Atherosclerosis (MESA) 
study. This study showed that NAFLD is associated 
with increased inflammation and CAC indepen-
dent of traditional risk factors, obesity, and the 
metabolic syndrome [62]. There was a graded as-
sociation between NAFLD, obesity, and the meta-
bolic syndrome with inflammation and CAC.
Measurement of carotid intima-media thick-
ness (CIMT) using ultrasound is a marker of sub-
clinical atherosclerosis. Carotid intima-media 
thickness is a strong predictor of future vascular 
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Table I. Studies showing association of non-alcoholic fatty liver disease and subclinical atherosclerosis
Author Year Country Study design Subjects Vascular 
pheno-
type
OR (95% CI) or 
p-value
Results 
significant 
after regression 
analysis
Santos [60] 2007 Brazil Cross-sectional 
analysis
505 CAC 1.49  
(1.00–2.21) 
Yes
Sung [59] 2012 South 
Korea
Cross-sectonal 
analysis
10,153 CAC 1.21  
(1.01–1.45)
Yes
Vanwagner 
[61]
2014 USA Cross-sectional 
analysis
2424 CAC
AAC
CAC: 1.72  
(1.29–2.28)
AAC: 1.85  
(1.40–2.46)
CAC: No
AAC: No
Rifai [62] 2015 USA Cross-sectional 
analysis
3976 CAC
Inflam-
mation 
(hsCRP)
CAC: 1.63  
(1.34–1.98)
hsCRP: 2.22  
(1.85–2.67)
CAC: Yes
hsCRP: Yes
Thakur [64] 2012 India Cross-sectional 
analysis
80 CIMT Average CIMT:  
4.8 (1.8–12.8)
Maximum CIMT:  
5.4 (2.0–14.4)
FMD: 11.7 (1.4–96.5)
Yes
Targher [65] 2005 Italy Case-control 
study
90 CIMT CIMT values:  
1.10 ±0.20 vs.  
0.84 ±0.13  
(p < 0.001)
Yes
Huang [66] 2011 China Cross-sectional 
analysis
8632 CIMT
baPWV
CIMT: 1.48  
(1.17–1.86)
baPWV: 1.50  
(1.29–1.75)
CIMT: Yes
baPWV: Yes
Kim [70] 2009 South 
Korea
Cross-sectional 
analysis
1021 CIMT 2.32  
(1.65–3.27)
Yes
Wang [69] 2009 Taiwan Prospective 
cohort study
169 CIMT ALT (every 10 IU/l 
increment)
1.44 (1.09–1.89) 
Yes
Agarwal 
[68]
2011 India Prospective 
cohort study
124 CIMT Mean CIMT 0.71  
±0.19 mm vs.  
0.67 ±0.22,  
p = 0.213
Yes
Kang [67] 2012 South 
Korea
Cross-sectional 
analysis
663 CIMT 1.98  
(1.44–2.73)
Yes
Ampuero 
[71]
2009–
2012
Meta-analysis 1947 CIMT 2.04  
(1.65–2.51)
Yes
Yu [79] 2014 China Cross-sectional 
analysis
1296 baPWV 1321 ±158 cm/s vs. 
1244 ±154 cm/s,  
p < 0.001
Yes
Li [78] 2014 China Prospective 
cohort study
1225 baPWV Significant both 
with and without 
presence of 
metabolic syndrome
Yes
Chung [77] 2015 Korea Cross-sectional 
analysis
2954 CAVI Mild NAFLD:  
1.27 (1.02–1.57)
Moderate-severe  
NAFLD: 1.78  
(1.37–2.31)
Yes
CAC – coronary artery calcium, AAC – abdominal aortic calcification, hsCRP – high-sensitivity C-reactive protein, CIMT – carotid intima-
media thickness, FMD – flow-mediated dilatation, baPWV – brachial-ankle pulse wave velocity, ALT – alanine aminotransferase, 
CAVI – cardioankle vascular index, NAFLD – non-alcoholic fatty liver disease. 
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events and better predicts risk of stroke compared 
to myocardial infarction [63]. A  cross-sectional 
study in an Indian population showed that sub-
jects with NAFLD had a higher average and maxi-
mum CIMT than controls. The presence of NAFLD 
was an independent predictor of having a  high 
average CIMT and high maximum CIMT after ad-
justing for obesity, the metabolic syndrome, insu-
lin resistance, and lipid parameters [64]. Another 
case control study that compared 50 consecutive 
patients recruited from clinics with 40 matched 
healthy volunteers showed a  statistically signif-
icant difference in CIMT between patients with 
NASH, simple steatosis, and controls. The differ-
ence in groups was statistically significant after 
adjustment for age, sex, homeostatic model as-
sessment-insulin resistance score, and the meta-
bolic syndrome [65]. 
A  large cross-sectional study on 8632 partici-
pants in China revealed a statistically significant 
higher CIMT in persons with NAFLD compared 
to those without NAFLD [66]. Logistic regression 
analysis showed that NAFLD conferred a 35% in-
creased odds of elevated CIMT independent of 
conventional risk factors and the presence of the 
metabolic syndrome [66]. A  larger meta-analysis 
included 4 studies [67–70]. This meta-analysis 
included 1,947 patients. Pathological CIMT was 
present in 35.1% of NAFLD patients compared to 
21.8% of patients without NAFLD (p < 0.0001). In 
meta-regression analysis, age and body mass in-
dex did not alter statistical significance [71]. 
The cardioankle vascular index (CAVI) rep-
resents stiffness of the entire arterial segment 
from the aorta to the ankle [72, 73]. Cardioankle 
vascular index reflects the progression of arterio-
sclerosis and is positively related to the severity 
of coronary atherosclerosis [74, 75]. Cardioankle 
vascular index also predicts carotid arterioscle-
rosis and stroke [75, 76]. In a  cross-sectional 
analysis of 2954 subjects, NAFLD was associated 
with a 42% increase in the risk of arterial stiff-
ness [77]. The risk of arterial stiffness increased 
with the severity of NAFLD. The association was 
statistically significant after adjustment for oth-
er risk factors including body mass index, waist 
circumference, smoking status, diabetes, and hy-
pertension [77]. 
Another measure of arterial stiffness is the bra-
chial-ankle pulse wave velocity (baPWV). A  pro-
spective study included 728 men and 497 women 
free of hypertension and diabetes mellitus [78]. 
These subjects were followed for 5 years. During 
the study period, baPWV changes were signifi-
cantly greater in subjects with NAFLD than in sub-
jects without NAFLD. Multiple regression analysis 
revealed that NAFLD is an independent and signif-
icant predictor for changes of baPWV [78]. Anoth-
er cross- sectional study in a Chinese population 
included 1296 non-obese, non-hypertensive and 
non-diabetic young and middle-aged subjects un-
dergoing routine medical check-ups [79]. Subjects 
with NAFLD had a significantly higher level of baP-
WV than the controls (1321 ±158 cm/s vs. 1244 
±154 cm/s; p < 0.001). The prevalence of NAFLD 
was higher in the increased baPWV group ver-
sus the normal baPWV group (29.3% vs. 16.9%; 
p < 0.001). Multiple liner logistic regression anal-
ysis revealed that NAFLD was positively and inde-
pendently associated with baPWV [79]. Another 
study also showed that subjects with NAFLD had 
a  higher baPWV as compared to those without 
NAFLD (1665 ±424 cm/s vs. 1558 ±430 cm/s; 
p < 0.0001) [66]. Logistic regression revealed 
a  30% increased odds of elevated baPWV, inde-
pendent of conventional risk factors and the pres-
ence of the metabolic syndrome [66]. 
Non-alcoholic fatty liver disease and 
atherosclerotic cardiovascular disease
Multiple epidemiological studies have linked 
NAFLD to increased cardiovascular disease risk 
[80, 81] (Table II). A  prospective observational 
study included 1637 apparently healthy Japanese 
men and women followed for a period of 5 years 
[15]. Among 1221 participants available for out-
come analysis, the incidence of atherosclerotic 
cardiovascular disease (CHD, ischemic stroke, and 
cerebral hemorrhage) was higher in subjects with 
NAFLD at baseline than those without NAFLD. 
Multivariate analyses indicated that NAFLD was 
a predictor of cardiovascular disease independent 
of conventional risk factors (OR = 4.12; 95% CI: 
1.58–10.75; p = 0.004) [15]. 
A  large prospective cohort study in a Chinese 
university hospital recruited 612 consecutive 
patients undergoing coronary angiography [16]. 
Coronary artery disease was present in 84.6% of 
the patients with NAFLD versus 64.1 % without 
NAFLD. The association was statistically signif-
icant after adjusting for demographics and the 
metabolic syndrome (OR = 2.31; 95% CI: 1.46–
3.64). During 87-week follow-up NAFLD did not 
predict cardiovascular mortality or morbidity [16]. 
The association of NAFLD and CAD was investi-
gated in type 2 diabetic patients. A  total of 273 
diabetic patients without liver disease undergoing 
coronary CT angiography were enrolled [82]. Cor-
onary artery disease was defined by the presence 
of coronary plaques, and significant CAD was de-
fined as the presence of ≥ 50% stenosis in at least 
one coronary artery. No association was found be-
tween NAFLD and CAD. However, after adjustment 
for age, gender, obesity, hypertension, smoking 
status and serum low-density lipoprotein (LDL) 
cholesterol as coronary risk factors, NAFLD was 
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associated with significant CAD in type 2 diabetics 
(OR = 2.128; 95% CI: 1.035–4.377) [82]. 
A  prospective study in 80 patients with the 
metabolic syndrome undergoing coronary an-
giography evaluated the association between 
NAFLD and CAD severity [83]. Coronary angiogra-
phy showed involvement of more vessels (2.5 ±0.9 
vs. 1.0 ±1.0; p < 0.001) and more severe CAD severi-
ty scores (Gensini scores, 90.2 ±40.0 vs. 36.4 ±28.9; 
p < 0.001) among patients with NAFLD. In multi-
variate regression analysis, NAFLD was the only 
independent factor affecting CAD severity score 
Table II. Studies showing association of non-alcoholic fatty liver disease with coronary artery disease
Author Year Country Study design Subjects Findings Risk estimates
Hamaguchi 
[15]
2007 Japan Prospective 
observational 
study
1637
(1221 
available 
for 
analysis)
1. Higher incidence of ASCVD in 
NAFLD subjects
2. NAFLD was a predictor of ASCVD 
independent of conventional risk 
factors
OR = 4.12;  
95% CI: 
1.58–10.75;  
p = 0.004
Wong [16] 2011 China Prospective 
cohort study
612 1. CAD was more common in 
patients with NAFLD
2. NAFLD is associated with CAD 
independent of other metabolic 
factors
OR = 2.31;  
95% CI: 
1.46–3.64
Idilman 
[82]
2007–
2010
Turkey Cross-
sectional 
retrospective
study
273 NAFLD was associated with 
significant CAD (defined as ≥ 50% 
stenosis, at least in one coronary 
artery) in type 2 diabetics
OR = 2.128;  
95% CI:  
1.035–4.377
Alper [83] 2008 Turkey Prospective 
cohort study
80 1. More vessels involved among 
patients with NAFLD as compared 
to patients without NAFLD
2. NAFLD is associated with more 
severe CAD
Number of 
vessels  
(2.5 ±0.9 vs. 
1.0 ±1.0;  
p < 0.001).
CAD severity 
scores  
(90.2 ±40.0 vs. 
36.4 ±28.9;  
p < 0.001)
Acikel [84] 2009 Turkey Cross-
sectional 
analysis
355 NAFLD has an independent effect 
on CAD and Gensini score
CAD (OR = 
2.58; p < 0.01)
Gensini Score 
(OR = 2.02;  
p < 0.05)
Sun [85] 2011 China Cross-
sectional 
analysis
542 1. NAFLD independently increased 
the risk for CAD
2. NAFLD was significantly more 
common in patients as CAD 
severity increased
OR = 7.585;  
95% CI:  
4.617–12.461
Arslan [88] 2012 Turkey Cross-sectional 
analysis
151 1. NAFLD was more prevalent 
in patients with poor coronary 
collateral circulation
2. Mean Rentrop collateral score 
was significantly lower in patients 
with NAFLD
1. 82.9% vs. 
49.4%;  
p < 0.001
2. 1.2 ±1.2 vs. 
2.1 ±0.9;  
p < 0.001
Targher 
[14]
2000–
2005
Italy Prospective 
nested case-
control study
2103 NAFLD was significantly associated 
with increased cardiovascular 
disease among type 2 diabetics 
independent of traditional 
risk factors and the metabolic 
syndrome
OR = 1.84;  
95% CI:  
1.4–2.1;  
p < 0.001
Pisto [13] 1991–
2009
Finland Population 
based 
randomly 
recruited 
cohort
988 Severe liver fat content predicted 
the risk of future cardiovascular 
events after adjustment for age, 
gender, and study group
HR = 1.92;  
95% CI:  
1.32–2.80
ASCVD – atherosclerotic cardiovascular disease, NAFLD – non-alcoholic fatty liver disease, CAD – coronary artery disease.
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[83]. Another study investigated cross-sectional 
analysis of 355 patients undergoing coronary an-
giography and showed a similar conclusion [84]. 
Univariate analysis showed that the presence of 
NAFLD has independent effects on CAD (OR = 2.58; 
p < 0.01) and also independently affects Gensini 
score (OR = 2.02; p < 0.05) [84]. Sun et al. enrolled 
542 patients planned to undergo coronary angi-
ography [85]. Abdominal computed tomography 
(CT) was performed before coronary angiogra-
phy to detect NAFLD. Logistic regression analysis 
showed that the presence of NAFLD independent-
ly increased the risk of CAD seen on coronary an-
giography (OR = 7.585; 95% CI: 4.617–12.461). 
Non-alcoholic fatty liver disease was seen signifi-
cantly more common in patients as the CAD sever-
ity increased [85].
Coronary collateral development has been 
shown to improve survival in patients with CAD 
[86]. The presence of the metabolic syndrome and 
associated insulin resistance have been shown to 
be associated with poor collateral development 
[87]. Arslan et al. enrolled 151 consecutive non-di-
abetic patients with stable angina pectoris with 
more than 95% stenosis in at least one major cor-
onary artery [76]. Non-alcoholic fatty liver disease 
was more prevalent in patients with poor collater-
al development (82.9% vs. 49.4%; p < 0.001). The 
mean Rentrop collateral score was significantly 
lower in patients with NAFLD (1.2 ±1.2 vs. 2.1 
±0.9; p < 0.001). Non-alcoholic fatty liver disease 
was significantly related to poor circulation (OR = 
6.20; 2.61–14.75) after logistic regression analysis 
was performed using factors associated with poor 
collateral development [88].
Targher et al. carried out a prospective-nested 
case-control study in 2103 type 2 diabetics free 
of cardiovascular disease at baseline [14]. During 
a 5-year follow-up, 248 participants subsequently 
developed nonfatal cardiac event, ischemic stroke 
or cardiovascular death. Four hundred ninety-six 
subjects that remained free of diagnosed car-
diovascular disease were selected as controls. 
Non-alcoholic fatty liver disease was significantly 
associated with an increased atherosclerotic car-
diovascular disease risk (OR = 1.84; 95% CI: 1.4–
2.1; p < 0.001) after adjustment for age, sex, smok-
ing history, diabetes duration, hemoglobin A1c, 
LDL cholesterol, liver enzymes, and use of med-
ications. The risk was attenuated but stayed 
statistically significant after adjustment for the 
metabolic syndrome [14]. Pisto et al. followed 
988 Finnish participants from 1991–2009. Pa-
tients were divided in three groups based on liver 
fat content. During the follow-up period, 13.5% 
of participants with non-fatty liver, 24.2% with 
moderate liver fat content, and 29.2% with se-
vere fatty liver experienced a cardiovascular event 
(p < 0.001). Severe liver fat content predicted the 
risk of future cardiovascular event when adjust-
ed for age, gender, and study group (HR = 1.92; 
95% CI: 1.32–2.80). The risk remained statisti-
cally significant (HR = 1.74, 95% CI: 1.16–2.63) 
after further adjustment for smoking, alcohol 
consumption, LDL cholesterol, body mass index, 
and systolic blood pressure, but disappeared after 
further adjustment for the QUICKI (Quantitative 
Insulin Sensitivity Check Index) [13]. 
Non-alcoholic fatty liver disease is associated 
with a higher average CIMT, maximum CIMT and 
presence of pathological CIMT [64, 65, 71]. Carotid 
intima-media thickness predicts the risk of future 
atherosclerotic cardiovascular disease includ-
ing stroke [63]. However, there are inconclusive 
data linking NAFLD with stroke. A cross-sectional 
study studied the association of acute ischemic 
stroke with biochemical markers of NAFLD [89]. 
Elevated alanine aminotransferase (ALT), ≥ 95th 
percentile was used as the criterion for the bio-
chemical presence of inflammatory NAFLD. The 
odds ratio for stroke in patients with an elevat-
ed ALT was 3.5 (95% CI: 1.7–7.6) and it was 3.3 
(95% CI: 1.3–8.4) after adjustment for age, sex, 
current smoking, current heavy alcohol intake, 
history of hypertension, atrial fibrillation, LDL cho-
lesterol, serum glucose, and serum creatinine [89]. 
Another case control study included 110 brain 
magnetic resonance imaging confirmed ischemic 
stroke patients and 110 age-and sex-matched con-
trols [90]. Liver ultrasonography was performed to 
detect NAFLD. Non-alcoholic fatty liver disease was 
found in 47 (42.7%) of ischemic stroke patients 
and 25 (22.7%) of controls. After adjusting for age 
and sex, NAFLD was significantly associated with 
ischemic stroke (OR = 2.15; 95% CI: 1.25–3.71). 
However, the association lost statistical signifi-
cance after adjusting for confounding risk factors 
including body mass index, waist circumference, 
smoking, and diabetes mellitus [90]. 
Treatment of non-alcoholic fatty liver disease
Treatment of NAFLD risk factors is the first line 
treatment strategy for NAFLD. Various lifestyle 
modifications have shown benefit in NAFLD. These 
include weight reduction [91, 92], reduced calorie 
intake, exercise alone even without weight loss 
[48–50]. A weight reduction achieved by bariatric 
procedures has also shown significant benefit in 
NAFLD [44–46]. 
Several studies have studied the effectiveness 
of metformin in NAFLD [93]. The results have been 
inconsistent with some studies showing benefit 
[94, 95], while others not showing any significant 
benefit [96, 97]. Based on available evidence, cur-
rent guidelines do not recommend metformin as 
a  specific treatment for liver disease in patients 
with NAFLD [1]. 
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Thiazolidinediones (TZDs) increase hepatic li-
pogenesis and insulin sensitivity by activating 
peroxisomal proliferator activated receptor-γ 
(PPAR-γ) [98]. Among TZDs, rosiglitazone and pi-
oglitazone have been studied the most. In a ran-
domized placebo-controlled clinical trial, rosiglita-
zone improved steatosis and transaminase level 
despite weight gain at the end of 1 year [99]. Lon-
ger therapy did not show additional improvement 
in steatosis despite a maintained effect on insulin 
sensitivity and transaminase levels [100]. Piogli-
tazone also showed significant improvement in 
fibrosis and hepatocellular injury after 12 months 
of treatment [101]. The results of another larger 
study did not reach statistical significance [102]. 
Overall evidence favors use of TZDs; however, cau-
tion should be taken in view of their cardiovascu-
lar adverse effects.
Liraglutide is a  long-acting human gluca-
gon-like peptide-1 (GLP-1) analog. Apart from 
glucose-reducing effects, liraglutide is associated 
with decreased level of pro-inflammatory cyto-
kines [103]. In a  phase 2 clinical trial, liragltide 
use was associated with greater odds of resolu-
tion of NASH (relative risk 4.3; 95% CI: 1.0–17.7; 
p = 0.019) [104]. Another study involving 8 months 
of liraglutide use in patients with type 2 diabetes 
mellitus and NAFLD has shown significantly re-
duced CIMT, a marker of subclinical atherosclerosis 
[105]. This effect was independent of glucometa-
bolic changes. Further studies are needed to vali-
date these findings and to advocate use of liraglu-
tide in NAFLD. 
Among lipid lowering drugs, statins and poly-
unsaturated fatty acids (PUFA) have shown ben-
efit in NAFLD. In a cross sectional study of 2578 
patients undergoing ultrasound, statin use of 
more than 2 years duration and body mass in-
dex more than 27.5 kg/m2 was associated with 
lower prevalence of steatosis (OR = 0.30, 95% CI: 
0.11–0.81) [106]. Clinical studies with atorvastatin 
have shown improvement in steatosis [107] and 
delayed progression of NAFL to NASH [108]. The 
current guidelines allow use of statins to treat 
dyslipidemia in patients with NAFLD but do not 
recommend their use to specifically treat NAFLD 
[1]. N-3 PUFA (omega-3 fatty acids) have also 
shown promising results in patients with NAFLD 
[109]. Based on current evidence, they are not rec-
ommended to specifically treat NAFLD, but may 
be considered as first line agents to treat hypertri-
glyceridemia in patients with NAAFLD [1].
Oxidative stress is one of the important hits 
in NAFLD pathogenesis. Anti-oxidant property of 
Vitamin E has been studied as a possible thera-
peutic intervention with some success [102]. It is 
recommended as a first-line pharmacotherapy for 
biopsy-proven NASH in non-diabetic patients [1].
Other potential treatments include N-acetyl cys-
teine, vitamin D, ursodeoxycholic acid and pentox-
ifylline [110]. Further studies are needed to assess 
the therapeutic effects of these agents in NAFLD. 
Conclusions
The majority of the studies discussed indicate 
that NAFLD is associated with cardiovascular dis-
ease. NAFLD affects multiple aspects of cardiovas-
cular diseases. Non-alcoholic fatty liver disease is 
associated with subclinical atherosclerosis and ar-
terial stiffness. The popular notion used to be that 
this association is due to shared risk factors such 
as obesity, metabolic syndrome, and diabetes mel-
litus among others. However, multiple studies have 
proved this association to be independent of the 
metabolic syndrome and traditional cardiovascular 
risk factors. These studies used CAC and CIMT as 
markers of subclinical atherosclerosis while CIMT 
and baPWV were used as markers of arterial stiff-
ness (Table I). One of the prospective studies also 
showed that NAFLD independently and significant-
ly predicted changes in baPWV [78]. 
Additionally the study by Chung et al. also 
showed association between NAFLD and subclin-
ical atherosclerosis in NAFLD severity-dependent 
manner [77]. Multivariate analysis showed a  se-
verity-dependent relationship between NAFLD 
and arterial stiffness (moderate-severe NAFLD: 
OR = 1.97, 95% CI: 1.28–3.01, p for trend = 0.002) 
in age group less than 55 years [77]. A study eval-
uating lipid profile among patients with NAFLD 
showed that NASH patients had lower levels of 
larger LDL1 and increased levels of small dense 
LDL3 and LDL4 compared to patients with simple 
steatosis [111]. This deranged lipid profile may 
partly explain increased risk of atherosclerosis 
and cardiovascular disease in patients with NASH 
compared to NAFL patients [112].  
Epidemiological data exist to link CAD directly 
to NAFLD. These studies have shown a higher inci-
dence of CAD, a higher prevalence of CAD, greater 
severity of CAD, a higher risk of future cardiovas-
cular event, and increased atherosclerotic cardio-
vascular disease among subjects with NAFLD as 
compared to subjects without NAFLD (Table II). 
Most of these studies were adjusted for the pres-
ence of conventional risk factors shared by NAFLD 
and CAD. Physicians treating NAFLD should be 
cognizant of these associations and should ac-
tively look out for symptoms of CAD in this popu-
lation, facilitating early therapeutic interventions.
Arslan et al. showed that NAFLD was associat-
ed with poor coronary collateral development [88]. 
Insulin resistance [59, 80], oxidative stress [9], 
worsening inflammatory state [9, 62], and endo-
thelial dysfunction [113] have all been implicated 
in the pathogenesis of cardiovascular disease in 
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NAFLD. The current understanding is that insu-
lin resistance is responsible for resistance to the 
antilipolytic effect of insulin and combined with 
visceral and pathological ectopic fat accumulation 
of NAFLD lead to an increased availability of free 
fatty acids [80]. The increased availability of free 
fatty with ongoing chronic subclinical inflamma-
tion, increased oxidative stress, and endothelial 
dysfunction promotes atherosclerosis and a dys-
functional physiological state with poor cardio-
vascular outcomes [80, 81]. Even though strong 
epidemiological evidence is available linking 
NAFLD with subclinical atherosclerosis and athero-
sclerotic vascular disease, our knowledge of the 
biochemical pathways contributing to this asso-
ciation is incomplete. More studies are needed to 
understand the underlying biochemical pathways 
and markers responsible for above findings which 
could lead to development of needed therapeutic 
interventions. 
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